文献速递皮肤肿瘤

nfP2X7靶向抗体外用治疗基底细胞癌的I期临床试验

A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma.
PubMed 文献 · Br J Dermatol · 2017-06-11

这项开放标签I期试验在三个皮肤科诊所评估了含10%羊多克隆抗nfP2X7抗体软膏(BIL010t)每日两次外用28天治疗原发性基底细胞癌的安全性和耐受性。65%患者病灶面积缩小,组织学显示3例完全缓解、9例部分缓解、8例稳定。

要点

  • 抗nfP2X7抗体软膏外用28天耐受性良好,无全身吸收证据。
  • 65%的基底细胞癌患者病灶面积缩小,组织学见3例完全缓解。
  • 常见不良事件为局部红斑、瘙痒、干燥和疼痛。

核心结论

  • 抗nfP2X7抗体(BIL010t)为基底细胞癌提供了一种新颖、安全且耐受性良好的局部治疗。

研究设计与样本

  • 开放标签I期临床试验在三个皮肤科诊所开展,评估10%羊多克隆抗nfP2X7抗体软膏每日两次外用28天。
  • 主要终点为安全性、耐受性和药代动力学,并评估病灶大小变化及治疗前后组织学。

主要发现

  • 治疗依从性很高,耐受性良好,最常见不良事件为治疗部位红斑、瘙痒、干燥和疼痛。
  • 无羊抗体全身渗透的证据。
  • 治疗28天后,65%患者病灶面积缩小,20%无变化,15%增大。
  • 治疗后切除标本组织病理显示8例稳定疾病、9例部分缓解、3例完全缓解。

临床怎么用

  • 对于原发性基底细胞癌,可考虑外用抗nfP2X7抗体软膏作为潜在的新治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Expression of P2X7 , an ATP-gated calcium channel, increases cancer cell proliferation and invasiveness. A variant of P2X7 (termed nfP2X7 ), in which a normally hidden epitope (E200) is exposed for antibody binding, is observed in a variety of different cancers. OBJECTIVES: To investigate the safety, tolerability and pharmacokinetics and assess indicative efficacy of a novel antibody ointment as a therapeutic for basal cell carcinoma (BCC). METHODS: An open-label, phase I clinical trial was undertaken at three dermatology clinics to evaluate the safety and tolerability of topical administration of an ointment containing 10% sheep polyclonal anti-nfP2X7 antibodies (BIL010t) to primary BCC lesions twice daily for 28 days. Twenty-one patients with primary BCC lesions at least 0·5 cm2 in area and less than 2·0 cm in diameter were enrolled. The primary end points were safety, tolerability and pharmacokinetics. Change in lesion size after treatment was determined and histology was performed on pretreatment and end-of-treatment (EOT) biopsies. RESULTS: Compliance was very high, with treatment being well tolerated. The most common adverse events were treatment site erythema, pruritus, dryness and pain. There was no evidence of systemic penetration of the sheep antibody. Lesions were measured prior to and after 28 days of treatment, with 65% of patients showing a reduction in lesion area, 20% showing no change and 15% showing an increase. Histopathology of post-treatment excision of lesion sites showed eight patients with stable disease, nine with partial response and three with complete response. CONCLUSIONS: Antibodies against nfP2X7 (BIL010t) provide a novel, safe and well-tolerated treatment for BCC.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gilbert SM, Gidley Baird A, Glazer S, et al. A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol. 2017. PMID: 28150889. doi:10.1111/bjd.15364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。